{"id":448611,"title":"Case studies: Handbook for health care professionals on biosimilar biologic drugs  - Canada.ca","sourceCode":"hc","sourceName":"Health Canada","language":"en","captureDate":"2026-01-03","captureTimestamp":"2026-01-03T17:18:15.103000+00:00","jobId":6,"originalUrl":"https://www.canada.ca/en/health-canada/services/drugs-health-products/biologics-radiopharmaceuticals-genetic-therapies/biosimilar-biologic-drugs/handbook-healthcare-professionals/case-studies.html?wbdisable=false","snippet":"Handbook for health care professionals on biosimilar biologic drugs: Case studies Overview About Data requirements Immunogenicity Authorization of biosimilars Monitoring Access to biosimilars Appendices Case studies On this page Kanjinti, a biosimilar to Herceptin Inflectra…","rawSnapshotUrl":"/api/snapshots/raw/448611","browseUrl":"https://replay.healtharchive.ca/job-6/20260103171815/https://www.canada.ca/en/health-canada/services/drugs-health-products/biologics-radiopharmaceuticals-genetic-therapies/biosimilar-biologic-drugs/handbook-healthcare-professionals/case-studies.html?wbdisable=false#ha_snapshot=448611","mimeType":"text/html","statusCode":200,"captureBackend":"browsertrix","captureFidelity":"high"}